|

Surufatinib Clinical Trials

7 actively recruiting trials

Also known as: HMPL-012, SULANDA

Pipeline

Phase 2: 6Phase 4: 1

Top Sponsors

Sun Yat-sen University2
Shanghai Zhongshan Hospital1
Shanghai Chest Hospital1
Peking University1
Fudan University1

Indications

Cancer7
Lung Cancer2
Consolidation Therapy1
Adenocarcinoma of Small Intestine1
Pulmonary Neuroendocrine Tumor1

Other7 trials

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

Phase 2

Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

Phase 2

Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms

Phase 4

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)

Phase 2

Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors

Phase 2

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

Phase 2

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.